Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🚫 This provider appears on the OIG List of Excluded Individuals/Entities (LEIE)
Exclusion type: 1128a4 · Date: 20260120 · State: NY
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
31,741
Total Claims
$2.9M
Drug Cost
1,192
Beneficiaries
$2,418
Cost/Patient
Risk Score Breakdown 47/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-10%
Opioid rate vs peers
2.0% vs 2.2% avg
+71%
Cost per patient vs peers
$2,418 vs $1,411 avg
+26%
Brand preference vs peers
13.4% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
2.0%
Opioid Rate
642
Opioid Claims
$28K
Opioid Cost
4.7%
Long-Acting Rate
Brand vs Generic
Brand: 4,167 claims · $2.2M
Generic: 26,963 claims · $685K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 555 | $272K |
| Dulaglutide | 217 | $190K |
| Sitagliptin Phosphate | 162 | $88K |
| Rivaroxaban | 161 | $84K |
| Insulin Aspart | 154 | $66K |
| Empagliflozin | 112 | $65K |
| Semaglutide | 57 | $56K |
| Fluticasone/Vilanterol | 118 | $49K |
| Insulin Glargine,hum.Rec.Anlog | 122 | $45K |
| Fluticasone/Umeclidin/Vilanter | 62 | $42K |
| Paliperidone Palmitate | 12 | $42K |
| Sacubitril/Valsartan | 66 | $38K |
| Insulin Detemir | 64 | $35K |
| Linagliptin | 87 | $35K |
| Mirabegron | 72 | $31K |
Prescribing Profile
Patient Profile
74
Avg Age
51%
Female
2.45
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About